Ajanta Pharma denies alert from USFDA, says supply is on
New Delhi : Drug firm Ajanta Pharma said that there is no import alert by the USFDA on the company's manufacturing unit in Aurangabad and it continues to supply to the US market.
"We want to clarify that there is no import alert on us by USFDA and we continue to supply to US market," Ajanta Pharma said in a BSE filing.
There has been media reports saying the company has got import alert from US FDA for its Paithan unit at Aurangabad.
Shares of Ajanta Pharma were trading 4.16 per cent lower at Rs 1,709.50 on BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd